DNA Methylation of Phosphatase and Actin Regulator 3 Detects Colorectal Cancer in Stool and Complements FIT

Abstract

Using a bioinformatics-based strategy, we set out to identify hypermethylated genes that could serve as biomarkers for early detection of colorectal cancer (CRC) in stool. In addition, the complementary value to a Fecal Immunochemical Test (FIT) was evaluated. Candidate genes were selected by applying cluster alignment and computational analysis of promoter regions to microarray-expression data of colorectal adenomas and carcinomas. DNA methylation was measured by quantitative methylation-specific PCR on 34 normal colon mucosa, 71 advanced adenoma, and 64 CRC tissues. The performance as biomarker was tested in whole stool samples from in total 193 subjects, including 19 with advanced adenoma and 66 with CRC. For a large proportion of these series, methylation data for GATA4 and OSMR were available for comparison. The complementary value to FIT was measured in stool subsamples from 92 subjects including 44 with advanced adenoma or CRC. Phosphatase and Actin Regulator 3 (PHACTR3) was identified as a novel hypermethylated gene showing more than 70-fold increased DNA methylation levels in advanced neoplasia compared with normal colon mucosa. In a stool training set, PHACTR3 methylation showed a sensitivity of 55% (95% CI: 33-75) for CRC and a specificity of 95% (95% CI: 87-98). In a stool validation set, sensitivity reached 66% (95% CI: 50-79) for CRC and 32% (95% CI: 14-57) for advanced adenomas at a specificity of 100% (95% CI: 86-100). Adding PHACTR3 methylation to FIT increased sensitivity for CRC up to 15%. PHACTR3 is a new hypermethylated gene in CRC with a good performance in stool DNA testing and has complementary value to FIT. Cancer Prev Res; 5(3); 464-72. Ó2011 AACR.

DNA Methylation Biomarkers for Noninvasive Diagnosis of Colorectal Cancer

“…36) and VIM. About the later, several works have been published reporting quite diverse sensitivity estimations of VIM for CRC detection in stool samples, ranging from 38% to 81% (reviewed in ref.…”

Distinguishable Prognostic Signatures of Left- and Right-Sided Colon Cancer: a Study Based on Sequencing Data

“…Among the abovementioned genes, the PHACTR protein family is closely related to cell motivity and morphogenesis by regulating the actin cytoskeleton [25]. PHACTR3 is a new hypermethylated gene in CRC exhibiting good performance in stool DNA testing and has complementary value to the fecal immunochemical test in colorectal cancer [26]. Hypermethylation of the PHACTR3 promoter measured in stool samples could be used as a colorectal cancer biomarker and provide prognostic information [27].…”

The diagnostic value of DNA hypermethylation in stool for colorectal cancer: A meta-analysis

“…In the year of 2012, about 103,170 new cases [1] China 2014 22 18 2 30 MSP Ahlquist et al [2] Ireland 2012 214 38 29 264 QuARTS Xu et al [3] China 2012 20 10 1 29 MSP Kang et al [4] China 2011 52 8 4 26 MSP Zhang et al [5] China 2011 52 8 4 26 MSP Ahlquist et al [6] Ireland 2012 26 4 5 41 QuARTS Bosch et al [7] Holland 2012 40 25 4 97 qMSP Azuara et al [8] Spain 2010 25 13 0 20 MS-MCA Tang et al [9] China 2011 142 27 2 28 MSP Baek et al [10] South Korea 2009 9 13 2 36 MSP Li et al [11] United States 2009 9 13 2 36 MSP Melotte et al [12] Holland 2009 42 33 3 72 qMSP Hellebrekers et al [13] Holland 2009 44 31 9 66 qMSP Mayor et al [14] Spain 2009 8 22 1 29 MS-MCA Kim et al [15] United States 2009 12 8 0 5 qMSP Nagasaka et al [16] Japan 2009 53 31 9 104 COBAR Glöckner et al [17] United States 2009 7 19 2 43 qMSP Wang and Tang [18] China 2008 60 9 2 28 Methylight Itzkowitz et al [19] United States 2008 9 13 2 36 MSP Huang et al [20] China 2007 50 2 1 23 MSP Itzkowitz [21] United States 2007 31 9 19 103 MSP Abbaszadegan [22] China (Hong Kong)…”